Development of angiotensin II type 1 receptor antibodies in patients with temporary mechanical circulatory support.

Authors

• Maria T Gamero
• Mark Liotta
• Yevgeniy Brailovsky
• Gregory Gibson
• Rene Alvarez
• Patricia Uber
• Yanping Huang
• Indranee Rajapreyar

Publication/Presentation Date

2-1-2024

Abstract

Angiotensin II type 1 receptor antibodies (AT1R-Ab) are among the most investigated type of non-human leukocyte antigen antibodies in solid organ transplantation, particularly given its association with allograft dysfunction. Some prior studies have described the development of AT1R antibodies in patients with durable mechanical circulatory support (MCS); however, the role of temporary MCS in autoantibody development is still uncertain. Given that the current United Network For Organ Sharing (UNOS) allocation system prioritizes heart transplant recipients in cardiogenic shock requiring temporary MCS, we investigated the development of these antibodies in 10 patients with temporary MCS (Impella 5.5

Volume

3

First Page

100016

Last Page

100016

ISSN

2950-1334

Published In/Presented At

Gamero, M. T., Liotta, M., Brailovsky, Y., Gibson, G., Alvarez, R., Uber, P., Huang, Y., & Rajapreyar, I. (2023). Development of angiotensin II type 1 receptor antibodies in patients with temporary mechanical circulatory support. JHLT open, 3, 100016. https://doi.org/10.1016/j.jhlto.2023.100016

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

40145103

Department(s)

Administration and Leadership

Document Type

Article